Yujiro Hata joined 5AM Ventures in August 2015 as an Executive-in-Residence. Mr. Hata also serves as Chief Executive Officer at Ideaya, a 5AM portfolio company developing therapeutics for oncology. From 2014 to August 2015, Yujiro served as Chief Operating Officer at immuno-oncology companies Flexus Biosciences and its spinout FLX Bio. He joined Flexus as a startup and led the company through its acquisition by Bristol-Myers Squibb in April 2015. While at Flexus, Yujiro oversaw all business operations, corporate strategy and M&A and licensing. From 2010 through its acquisition in October 2013 by Amgen, Mr. Hata was Vice President, Corporate Development & Strategy at Onyx Pharmaceuticals, where he held various leadership roles including Head of Strategy and Strategic Asset Management and Head of M&A and Licensing. From 2002 to 2010, Mr. Hata served as Vice President, Senior Vice President and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA). He earlier served in roles spanning business and R&D at McKinsey & Company, ImClone and Columbia Medical School. Mr. Hata obtained his MBA at Wharton, as a Henry J Kaiser recipient, and completed undergraduate studies in chemistry at Oxford University and Colorado College. He serves on the Board of Directors of Xencor (NASDAQ: XNCR) and the Board of Visitors of the Moores Cancer Center, at the University of California, San Diego. Mr. Hata is based in the San Francisco, CA office.
Copyright © 2017 5AM Venture Management LLC